ForteBio Repositioned to Focus on Delivering Breakthroughs in Early Stage Biologic Drug Development
Molecular Devices announces brand identity for its newly-formed biologics business unit
7 Nov 2018
Industry news
Molecular Devices LLC, a leader in protein and cell biology technologies, has announced a new, exciting brand for its recently created biologics solutions business unit. The business unit combines the industry leading ForteBio label-free technology platform with Molecular Devices’ Biologics Biotherapeutics portfolio of products, and henceforth will be known as ForteBio. It is accompanied by a new logo.
ForteBio’s mission is to fast-track timelines by removing hurdles in early stage biologics development through innovative technologies and workflow solutions. Its three core values aim to remove technical hurdles and workflow bottlenecks for its customers through best-in-class, high quality products and apply scientific expertise to solving customers’ research challenges through lasting partnerships.
CUSTOMER COMMITMENT: ForteBio’s solutions enable customers to make breakthroughs faster, help them be more productive, remove their technical hurdles and unlock their workflow bottlenecks.
QUALITY: ForteBio’s best in class products, technical know-how and first-class service empower our customers to be successful.
PARTNERSHIP: ForteBio knows the science behind its customer’s research and works with them as a trusted partner to find the best solutions for their research challenges.
“We are making great progress in hitting our milestones for the newly formed biologics business unit within Molecular Devices,” said Greg Milosevich, President of Molecular Devices. “We successfully defined our strategic plan earlier this summer aimed at taking market share in the fast growing early stage biologic drug R&D market and have assembled a strong commercial team to help us realize this goal. Our new brand identity and logo convey with great clarity our vision, mission and core values. With a refreshed brand, an energized team and new mission, I expect ForteBio will deliver important breakthroughs to power early stage biologic drug development.”